Understanding treatment patterns and patient-reported outcomes associated with the use of authorized generics and corresponding independent generics across multiple therapeutic areas

References

• US Food and Drug Administration. Generic drugs [Internet]. 2021; [cited 2021 Feb 10]. Available from: https://www.fda.gov/drugs/buying-using-medicine-safely/generic-drugs.
   Google Scholar
• US Food and Drug Administration. FDA list of authorized generic drugs [Internet]; 2021. [cited 2021 May 15]. Available from: https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/fda-list-authorized-generic-drugs.
   Google Scholar
• Burch HB, Burman KD, Cooper DS, et al. A 2013 survey of clinical practice patterns in the management of primary hypothyroidism. J Clin Endocrinol Metab. 2014;99(6):2077–2085.
   PubMed Web of Science ®Google Scholar
• Benvenga S. When thyroid hormone replacement is ineffective? Curr Opin Endocrinol Diabetes Obes. 2013;20(5):467–477.
   PubMedGoogle Scholar
• Taylor PN, Iqbal A, Minassian C, et al. Falling threshold for treatment of borderline elevated thyrotropin levels - balancing benefits and risks evidence from a large community-based study. JAMA Intern Med. 2014;174(1):32–39.
   PubMed Web of Science ®Google Scholar
• Vigário PDS, Vaisman F, Coeli CM, et al. Inadequate levothyroxine replacement for primary hypothyroidism is associated with poor health-related quality of life-a brazilian multicentre study. Endocrine. 2013;44(2):434–440.
   PubMed Web of Science ®Google Scholar
• Huo N, Chen L, Ullah Mishuk A, et al. Generic levothyroxine initiation and substitution among medicare and medicaid populations: a new user cohort study. Endocrine. 2020;68(2):336–348.
   PubMed Web of Science ®Google Scholar
• Hansen RA, Qian J, Berg R, et al. Comparison of generic-to-brand switchback rates between generic and authorized generic drugs. Pharmacotherapy. 2017;37(4):429–437.
   PubMed Web of Science ®Google Scholar
• Desai RJ, Sarpatwari A, Dejene S, et al. Comparative effectiveness of generic and brand-name medication use: a database study of US health insurance claims. PLoS Med. 2019;16(3):e1002763.
   PubMed Web of Science ®Google Scholar
• Hansen RA, Qian J, Berg RL, et al. Comparison of outcomes following a switch from a brand to an authorized versus independent generic drug. Clin Pharmacol Ther. 2018;103(2):310–317.
   PubMed Web of Science ®Google Scholar
• Keenum AJ, Devoe JE, Chisolm DJ, et al. Generic medications for you, but brand-name medications for me. Res Social Adm Pharm. 2012;8(6):574–578.
   PubMed Web of Science ®Google Scholar
• Dunne SS, Dunne CP. What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs. BMC Med. 2015;13:173.
   PubMed Web of Science ®Google Scholar
• Figueiras MJ, Alves NC, Marcelino D, et al. Assessing lay beliefs about generic medicines: development of the generic medicines scale. Psychol Health Med. 2009;14(3):311–321.
   PubMed Web of Science ®Google Scholar
• Faasse K, Martin LR, Grey A, et al. Impact of Brand or generic labeling on medication effectiveness and side effects. Health Psychol. 2016;35(2):187–190.
   PubMed Web of Science ®Google Scholar
• Desai RJ, Sarpatwari A, Dejene S, et al. Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study. BMJ. 2018;361:k1180.
   PubMedGoogle Scholar
• Fife D, Cepeda MS, Baseman A, et al. Medication changes after switching from CONCERTA® Brand methylphenidate HCl to a generic long-acting formulation: a retrospective database study. PLoS One. 2018;13(2):e0193453.
   PubMed Web of Science ®Google Scholar
• Rathe J, Larsen P, Andersen M, et al. Associations between generic substitution and patients’ attitudes, beliefs and experiences. Eur J Clin Pharmacol. 2013;69(10):1827–1836.
   PubMed Web of Science ®Google Scholar
• Gagne JJ, Choudhry NK, Kesselheim AS, et al. Comparative effectiveness of generic and Brand-name statins on patient outcomes: a cohort study. Ann Intern Med. 2014;161(6):400–407.
   PubMed Web of Science ®Google Scholar
• Choudhry NK, Denberg TD, Qaseem A. Improving adherence to therapy and clinical outcomes while containing costs: opportunities from the greater use of generic medications: best practice advice from the clinical guidelines committee of the American College of physicians. Ann Intern Med. 2016;164(1):41–49.
   PubMed Web of Science ®Google Scholar
• Shrank WH, Hoang T, Ettner SL, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006;166(3):332–337.
   PubMed Web of Science ®Google Scholar
• Devi R, Kanitkar K, Narendhar R, et al. A narrative review of the patient journey through the lens of non-communicable diseases in low- and Middle-income countries. Adv Ther. 2020;37(12):4808–4830.
   PubMed Web of Science ®Google Scholar
• Nicholas JA, Electricwala B, Lee LK, et al. Burden of relapsing-remitting multiple sclerosis on workers in the US: a cross-sectional analysis of survey data. BMC Neurol. 2019;19(1):13.
   PubMed Web of Science ®Google Scholar
• Rajagopalan K, Lee LK. Association between adherence to sodium channel blockers and patient-reported outcomes: analysis of US survey data among patients with epilepsy. Epilepsy Behav. 2019;99:106483.
   PubMed Web of Science ®Google Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682.
   PubMed Web of Science ®Google Scholar
• Kroenke K, Spitzer RL. The PHQ-9: a new depression diagnostic and severity measure. Psychiatr Ann. 2002;32(9):509–515.
   Web of Science ®Google Scholar
• Maruish M. User’s manual for the SF36v2 Health Survey. In Qual metr inc. 3rd ed. Lincoln, RI: QualityMetric Inc; 2011.
   Google Scholar
• Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271–292.
   PubMed Web of Science ®Google Scholar
• Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–1736.
   PubMed Web of Science ®Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353–365.
   PubMed Web of Science ®Google Scholar
• Aziz H, Hatah E, Makmor Bakry M, et al. How payment scheme affects patients’ adherence to medications? A systematic review. Patient Prefer Adherence. 2016;10:837–850.
   PubMed Web of Science ®Google Scholar
• Mann BS, Barnieh L, Tang K, et al. Association between drug insurance cost sharing strategies and outcomes in patients with chronic diseases: a systematic review. PLoS One. 2014;9(3):e89168–8.
   PubMed Web of Science ®Google Scholar
• Howard JN, Harris I, Frank G, et al. Influencers of generic drug utilization: a systematic review. Res Social Adm Pharm. 2018;14(7):619–627.
   PubMed Web of Science ®Google Scholar
• Mishuk AU, Qian J, Howard JN, et al. The association between patient sociodemographic characteristics and generic drug use: a systematic review and Meta-analysis. J Manag Care Spec Pharm. 2018;24(3):252–264.
   PubMed Web of Science ®Google Scholar
• Hong J, Novick D, Treuer T, et al. Predictors and consequences of adherence to the treatment of pediatric patients with attention-deficit/hyperactivity disorder in Central Europe and east asia. Patient Prefer Adherence. 2013;7:987–995.
   PubMed Web of Science ®Google Scholar
• Giral P, Neumann A, Weill A, et al. Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France. Eur Heart J. 2019;40(43):3516–3525.
   PubMed Web of Science ®Google Scholar
• Chin AL, Bentley JP, Pollom EL. Impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer. Cancer. 2019;125(3):374–381.
   PubMed Web of Science ®Google Scholar
• Simoens S, Sinnaeve PR. Patient co-payment and adherence to statins: a review and case studies. Cardiovasc Drugs Ther. 2014;28(1):99–109.
   PubMed Web of Science ®Google Scholar
• Lewey J, Shrank WH, Avorn J, et al. Medication adherence and healthcare disparities: impact of statin co-payment reduction. Am J Manag Care. 2015;21:696–704.
   PubMed Web of Science ®Google Scholar